Gelteq (GELS) Debt Ratio (2023 - 2025)

Gelteq's (GELS) quarterly Debt Ratio came in at 0.25 in Q4 2025, up 63.93% year-on-year from 0.15 in Q4 2024, and down 35.27% quarter-over-quarter from 0.39 in Q2 2025.

Gelteq (GELS) Debt Ratio (2023 - 2025) Analysis & Trends

Gelteq's Debt Ratio history runs 3 years deep, the most recent figure standing at 0.25 for Q4 2025.

  • On a quarterly basis, Debt Ratio rose 63.93% year-over-year to 0.25 in Q4 2025; TTM through Dec 2025 was 0.25, a 63.93% increase from a year earlier, with the FY2025 full-year figure at 0.39, up 111.44% from the prior year.
  • Debt Ratio eased to 0.25 in Q4 2025 per GELS's latest filing, from 0.39 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.39 in Q2 2025 and bottomed at 0.11 in Q2 2023.
  • The 3-year median for Debt Ratio is 0.19 (2024), against an average of 0.22.
  • Biggest YoY gain for Debt Ratio was 111.44% in 2025; the steepest drop was 63.93% in 2025.
  • Year by year, Debt Ratio stood at 0.11 in 2023, then jumped by 40.41% to 0.15 in 2024, then soared by 63.93% to 0.25 in 2025.
  • Per Business Quant, the three latest GELS Debt Ratio figures stand at 0.25 (Q4 2025), 0.39 (Q2 2025), and 0.15 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 0.26
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 0.42
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 0.60
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 0.29
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 0.10
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 0.39
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 0.29
10 Gelteq 740.00 -47,821.64 - 0.25

Historic Data

Download Data
DateValue
Dec 31, 2025 0.25
Jun 30, 2025 0.39
Dec 31, 2024 0.15
Jun 30, 2024 0.19
Jun 30, 2023 0.11